A Phase 2 Study of Brentuximab Vedotin With Chemotherapy in People With T-Cell Lymphoma

Share

Full Title

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas

Purpose

Brentuximab vedotin (BV) plus chemotherapy with the drugs cyclophosphamide, doxorubicin, and prednisone (CHP) is a standard treatment for T-cell lymphomas that make the CD30 protein. Researchers want to see if BV with an enhanced chemotherapy regimen that includes etoposide works better in people with T-cell lymphomas.

The people in this study have T-cell lymphoma that has not yet been treated and makes CD30. The drugs in this study are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have T-cell lymphoma that makes CD30 and has not yet been treated.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Robert Stuver’s office at 646-608-4308.

Protocol

24-139

Phase

Phase II (phase 2)

Investigator

Co-Investigators

ClinicalTrials.gov ID

NCT03113500